Expert Interview
Discussing the potential of AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy as an FDA approved option.
Ticker(s): AZN, IONSInstititution: Monument Health
- Neurologist at Monument Health Neurology and Rehabilitation.
- Currently manages 90 AIS patients per month and is able to discuss the abstract data on the Phase 2a Study of TMS-007.
- Medical interests include: medically resistant and different to control epilepsy, spell/seizure evaluation, and device therapy for epilepsy.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
